Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565654 | 0.88 | MEN1 (0.49) | L3MBTL1KMT2AMAPTALDH1A1MEN1 | |
| SCHEMBL6564731 | 0.86 | HSPB1 (0.45) | HSPB1L3MBTL1KMT2AMAPTALDH1A1 | |
| SCHEMBL6564830 | 0.86 | SMN1; SMN2 (0.41) | HSPB1L3MBTL1KMT2AMAPTALDH1A1 | |
| SCHEMBL6564760 | 0.86 | MAPT (0.46) | HSPB1L3MBTL1KMT2AMAPTALDH1A1 | |
| SCHEMBL6567602 | 0.83 | HSPB1 (0.40) | HSPB1L3MBTL1KMT2AMAPTALDH1A1 | |
| SCHEMBL6566841 | 0.83 | SMN1; SMN2 (0.48) | HSPB1L3MBTL1KMT2AMAPTALDH1A1 | |
| SCHEMBL6566670 | 0.82 | KMT2A (0.47) | L3MBTL1KMT2AMAPTALDH1A1MEN1 | |
| SCHEMBL6564414 | 0.81 | KMT2A (0.45) | HSPB1L3MBTL1KMT2AMAPTALDH1A1 | |
| SCHEMBL6564692 | 0.80 | ALOX5 (0.37) | L3MBTL1KMT2AMAPTALDH1A1MEN1 | |
| SCHEMBL6564797 | 0.79 | MAPT (0.41) | HSPB1L3MBTL1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | HSPB1 2636/4885L3MBTL1 2613/4885KMT2A 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.